US equities
|
INTC
$64.11
▼-30.37%
NVDA
$203.05
▼-4.97%
MU
$871.23
▼-6.75%
AMZN
$239.68
▼-1.69%
SNDK
$1,138.26
▼-14.42%
AMD
$497.59
▼-12.15%
AAPL
$344.05
▼-1.39%
GOOGL
$278.82
▼-1.76%
INTC
$64.11
▼-30.37%
NVDA
$203.05
▼-4.97%
MU
$871.23
▼-6.75%
AMZN
$239.68
▼-1.69%
SNDK
$1,138.26
▼-14.42%
AMD
$497.59
▼-12.15%
AAPL
$344.05
▼-1.39%
GOOGL
$278.82
▼-1.76%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Neuronetics, Inc. - Common Stock
(NQ:
STIM
)
2.240
-0.140 (-5.88%)
Delayed Quote
Updated: 3:43 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neuronetics, Inc. - Common Stock
< Previous
1
2
3
Next >
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
September 08, 2026
First-of-Its-Kind Integration Connects TrakStar and AdvancedMD, Delivering TMS Care Across Clinical, Operational, and Billing Workflows
From
Neuronetics; AdvancedMD
Via
GlobeNewswire
Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland
July 28, 2026
New location expands access to advanced mental health treatments while serving as Greenbrook's flagship innovation center and blueprint for future care delivery
From
Neuronetics
Via
GlobeNewswire
Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
June 02, 2026
New findings from the industry’s largest real-world TMS database reinforce NeuroStar’s leadership in advancing evidence-based mental health care
From
Neuronetics
Via
GlobeNewswire
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
May 14, 2026
First-of-its-kind partnership expands NeuroStar platform capabilities with advanced visualization technology designed to address evolving provider needs and support more personalized treatment...
From
Neuronetics
Via
GlobeNewswire
Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners
April 13, 2026
Policy Update Broadens Access to Innovative, Non-Drug Depression Treatment Across 26 States and Washington, D.C.
From
Neuronetics
Via
GlobeNewswire
TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
November 12, 2025
New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
October 30, 2025
New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite DNA Clinics
From
Neuronetics
Via
GlobeNewswire
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
September 17, 2025
Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services
From
Neuronetics
Via
GlobeNewswire
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
July 30, 2025
Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes dataset
From
Neuronetics
Via
GlobeNewswire
Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program
June 10, 2025
NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical innovation and excellence
From
Neuronetics
Via
GlobeNewswire
Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month
May 14, 2025
From
Neuronetics
Via
GlobeNewswire
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
March 31, 2025
Policy update increases access for millions covered by Evernorth Health Services
From
Neuronetics
Via
GlobeNewswire
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
January 29, 2025
Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
October 14, 2024
Data selected for oral presentation reinforce previous findings on safety and efficacy
From
Neuronetics
Via
GlobeNewswire
Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
September 25, 2024
Policy update increases access for millions covered by HCSC BlueCross BlueShield policies
From
Neuronetics
Via
GlobeNewswire
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
September 19, 2024
BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Releases Software Upgrades to Elevate Patient Care
September 16, 2024
Upgrades improve communication, streamline data management, and strengthen security
From
Neuronetics
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enstar Group Limited (Nasdaq – ESGR), PetIQ, Inc. (Nasdaq – PETQ), Greenbrook TMS, Inc. (OTC – GBNHF), GSE Solutions, Inc. (Nasdaq – GVP)
September 06, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories
September 03, 2024
NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University
August 20, 2024
Celebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility
From
Neuronetics
Via
GlobeNewswire
NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month
August 01, 2024
New initiative aims to provide information and resources for teen mental health amidst rising public health concerns
From
Neuronetics
Via
GlobeNewswire
Aetna Policy Update Expands TMS Availability for Adolescents With Depression
July 22, 2024
Coverage criteria consistent with recent FDA clearance for NeuroStar TMS
From
Neuronetics
Via
GlobeNewswire
California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults
July 11, 2024
NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal
From
Neuronetics
Via
GlobeNewswire
BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents
July 10, 2024
Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Launches Better Me Provider Program Nationwide
July 01, 2024
The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry
From
Neuronetics
Via
GlobeNewswire
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
June 13, 2024
Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024
From
Neuronetics
Via
GlobeNewswire
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
May 15, 2024
Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older
From
Neuronetics
Via
GlobeNewswire
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
May 01, 2024
The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance
From
Neuronetics
Via
GlobeNewswire
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
April 10, 2024
Lack of early symptom improvement is not predictive of final responder status
From
Neuronetics
Via
GlobeNewswire
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
March 25, 2024
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older
From
Neuronetics
Via
GlobeNewswire
< Previous
1
2
3
Next >
